Centre for Youth Mental Health - Research Publications

Permanent URI for this collection

http://hdl.handle.net/11343/250

Filters

2019 - 2019 1 2020 - 2021 2
Reset filters

Settings
Statistics
Citations
Start date: 2018 × Type: Conference Paper ×

Search Results

Now showing 1 - 3 of 3
  • Item
    No Preview Available
    Separating Clinical and Subclinical Depression by Big Data Informed Structural Vulnerability Index and Its impact on Cognition: ENIGMA Dot Product
    Kochunov, P ; Ma, Y ; Hatch, KS ; Schmaal, L ; Jahanshad, N ; Thompson, PM ; Adhikari, BM ; Bruce, H ; Chiappelli, J ; Van der vaart, A ; Goldwaser, EL ; Sotiras, A ; Ma, T ; Chen, S ; Nichols, TE ; Hong, LE (WORLD SCIENTIFIC, 2021-12)
  • Item
    Thumbnail Image
    Increases in controlled-release oxycodone utilisation following the subsidy of oxycodone with naloxone formulations: An Australian population-based study
    Schaffer, AL ; Karanges, EA ; Buckley, NA ; Wilson, A ; Degenhardt, L ; Larance, B ; Pearson, S-A (WILEY, 2019-01)
    PURPOSE: Despite increasing use of oxycodone/naloxone controlled-release (CR) in Australia, little is known about how it has affected the overall oxycodone CR market since its subsidy in 2011. METHODS: We used Pharmaceutical Benefits Scheme dispensing claims (2006-2016) and interrupted time series analysis to examine changes in the quarterly rates of dispensing of oral oxycodone CR formulations (oxycodone/naloxone CR and single-ingredient oxycodone CR) and new oxycodone CR treatment episodes. We also performed a retrospective cohort study in a sample of people initiating a new oxycodone CR treatment episode in 2009, 2012/2013, and 2016 to compare opioid utilisation patterns over time. RESULTS: The subsidy of oxycodone/naloxone CR was associated with a 1.6-fold increase in the growth rate of oxycodone CR dispensing, resulting from rapid uptake of low strength (≤5 mg) oxycodone/naloxone CR. In our cohort of initiators, the number of new oxycodone CR treatment episodes increased 2.1-fold between 2009 and 2016; in 2016, 91.4% of new treatment episodes involved oxycodone/naloxone CR. Comparing 2016 with 2009, we observed an increase in people initiating with a tablet strength less than or equal to 5-mg (risk difference [RD] = 21.1%, 95% CI, 19.9%-22.4%) in people initiating with no other opioid dispensing 90 days prior to initiation (RD = 5.2%, 3.8%-6.6%) and with no further opioid dispensing 90 days after initiation (RD = 8.8%, 7.4%-10.2%). CONCLUSIONS: After its subsidy, the uptake of low-dose oxycodone/naloxone CR was greater than expected if it were substituting the single-ingredient oxycodone CR, resulting in an expansion of the oxycodone CR market.
  • Item
    Thumbnail Image
    A chatbot architecture for promoting youth resilience
    Holt-Quick, C ; Warren, J ; Stasiak, K ; Williams, R ; Christie, G ; Hetrick, S ; Hopkins, S ; Cargo, T ; Merry, S (IOS Press, 2021-04-19)
    E-health technologies have potential to provide scalable and accessible interventions for youth mental health. As part of an ecosystem of e-screening and e-therapy tools for New Zealand young people, a dialog agent, Headstrong, has been designed to promote resilience with methods grounded in cognitive behavioral therapy and positive psychology. This paper describes the architecture underlying the chatbot. The architecture supports a range of over 20 activities delivered in a 4-week program by relatable personas. The architecture provides a visual authoring interface to its content management system. In addition to supporting the original adolescent resilience chatbot, the architecture has been reused to create a 3-week ‘stress-detox’ intervention for undergraduates, and subsequently for a chatbot to support young people with the impacts of the COVID-19 pandemic, with all three systems having been used in field trials. The Headstrong architecture illustrates the feasibility of creating a domain-focused authoring environment in the context of e-therapy that supports non-technical expert input and rapid deployment.